Jackman AL[au] - Search Results

Year	Number of Results
1980	1
1981	1
1983	1
1984	3
1985	1
1986	4
1987	2
1988	2
1989	6
1990	5
1991	9
1992	5
1993	12
1994	2
1995	10
1996	10
1997	5
1998	4
1999	4
2000	7
2001	4
2002	3
2003	2
2004	2
2005	2
2006	3
2007	1
2008	3
2009	1
2018	1
2022	0

1

Clarke SJ, Jackman AL, Harrap KR. Clarke SJ, et al. Among authors: jackman al. Adv Exp Med Biol. 1991;309A:7-13. doi: 10.1007/978-1-4899-2638-8_2. Adv Exp Med Biol. 1991. PMID: 1789273 Review. No abstract available.

2

Antifolates targeted specifically to the folate receptor.

Jackman AL, Theti DS, Gibbs DD. Jackman AL, et al. Adv Drug Deliv Rev. 2004 Apr 29;56(8):1111-25. doi: 10.1016/j.addr.2004.01.003. Adv Drug Deliv Rev. 2004. PMID: 15094210 Review.

3

Exploitation of the folate receptor in the management of cancer and inflammatory disease.

Leamon CP, Jackman AL. Leamon CP, et al. Among authors: jackman al. Vitam Horm. 2008;79:203-33. doi: 10.1016/S0083-6729(08)00407-X. Vitam Horm. 2008. PMID: 18804696 Review.

4

Folate-based thymidylate synthase inhibitors as anticancer drugs.

Jackman AL, Calvert AH. Jackman AL, et al. Ann Oncol. 1995 Nov;6(9):871-81. doi: 10.1093/oxfordjournals.annonc.a059353. Ann Oncol. 1995. PMID: 8624289 Free article. Review.

5

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, Raynaud F, Walton M, Eccles SA, Judson I, Jackman AL, Workman P. Banerji U, et al. Among authors: jackman al. Cancer Chemother Pharmacol. 2018 Nov;82(5):911-912. doi: 10.1007/s00280-018-3674-9. Cancer Chemother Pharmacol. 2018. PMID: 30173339

6

Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.

Jackman AL, Kimbell R, Ford HE. Jackman AL, et al. Eur J Cancer. 1999 Mar;35 Suppl 1:S3-8. doi: 10.1016/s0959-8049(99)00041-6. Eur J Cancer. 1999. PMID: 10645207 Review.

7

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.

Jackman AL, Boyle FT, Harrap KR. Jackman AL, et al. Invest New Drugs. 1996;14(3):305-16. doi: 10.1007/BF00194534. Invest New Drugs. 1996. PMID: 8958186 Review.

8

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M, Boyle FT. Jackman AL, et al. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82. doi: 10.1016/0959-8049(95)00166-g. Eur J Cancer. 1995. PMID: 7577036 Review.

9

The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694.

Jackman AL, Gibson W, Brown M, Kimbell R, Boyle FT. Jackman AL, et al. Adv Exp Med Biol. 1993;339:265-76. doi: 10.1007/978-1-4615-2488-5_26. Adv Exp Med Biol. 1993. PMID: 7513935 Review.

10

A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.

Jackman AL, Melin CJ, Kimbell R, Brunton L, Aherne GW, Theti DS, Walton M. Jackman AL, et al. Biochim Biophys Acta. 2002 Jul 18;1587(2-3):215-23. doi: 10.1016/s0925-4439(02)00084-4. Biochim Biophys Acta. 2002. PMID: 12084463 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results